secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2022-04-08T23:59:59+00:00
Accession:  0001831283-22-000021
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio appoints Wei Wei Chen as independent director and Audit Committee member
--------------------------------------------------------------------------------

- Wei Wei Chen appointed to LianBio Board as Class II director effective April 6, 2022; term ends at 2023 annual shareholder meeting.
- Chen also appointed to the Audit Committee of the Board.
- Chen brings 17+ years CFO experience, most recently at Starbucks China; previously CFO at Yum! Brands China and Sanofi Asia.
- No arrangement or understanding with any other person led to selection; no related-party transactions requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000021/0001831283-22-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000021/lian-20220406.htm
  HTML page:      https://secwatch.observer/filing/0001831283-22-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer